Let’s start up with the current stock price of ProQR Therapeutics N.V. (PRQR), which is $3.16 to be very precise. The Stock rose vividly during the last session to $3.18 after opening rate of $2.98 while the lowest price it went was recorded $2.91 before closing at $2.93.
ProQR Therapeutics N.V. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $3.78 on 01/03/23, with the lowest value was $0.53 for the same time period, recorded on 05/11/22.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
ProQR Therapeutics N.V. (PRQR) full year performance was 224.37%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, ProQR Therapeutics N.V. shares are logging -16.40% during the 52-week period from high price, and 496.23% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.53 and $3.78.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 799182 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the ProQR Therapeutics N.V. (PRQR) recorded performance in the market was -14.59%, having the revenues showcasing 112.08% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 251.03M, as it employees total of 181 workers.
Analysts verdict on ProQR Therapeutics N.V. (PRQR)
During the last month, 2 analysts gave the ProQR Therapeutics N.V. a BUY rating, 1 of the polled analysts branded the stock as an OVERWEIGHT, 5 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 2.21, with a change in the price was noted +2.24. In a similar fashion, ProQR Therapeutics N.V. posted a movement of +243.59% for the period of last 100 days, recording 2,107,643 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for PRQR is recording 0.34 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.29.
ProQR Therapeutics N.V. (PRQR): Technical Analysis
Raw Stochastic average of ProQR Therapeutics N.V. in the period of last 50 days is set at 54.42%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 84.62%. In the last 20 days, the company’s Stochastic %K was 49.15% and its Stochastic %D was recorded 56.36%.
Let’s take a glance in the erstwhile performances of ProQR Therapeutics N.V., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -14.59%. Additionally, trading for the stock in the period of the last six months notably improved by 292.55%, alongside a boost of 224.37% for the period of the last 12 months. The shares increased approximately by 3.27% in the 7-day charts and went down by 8.97% in the period of the last 30 days. Common stock shares were driven by 112.08% during last recorded quarter.
